§ Vernon CoakerTo ask the Secretary of State for Health what discussions he has had with drug companies266W on the reduction of the cost of beta interferon in the UK to the level of other European countries; and if he will make a statement. [23322]
§ Ms BlearsThe Department has held discussions with Schering, Biogen and Serono, the manufacturers of the three beta interferon products licensed in the United Kingdom, and with Aventis and Teva, who jointly market Copaxone (glatiramer), in relation to the possible provision of these therapies for patients with multiple sclerosis in a manner which could be considered to be cost effective. These discussions began on 5 September, after the Department and other consultees had received copies of the preliminary appraisal determination of the National Institute for Clinical Excellence, and are still continuing.
§ Mr. Laurence RobertsonTo ask the Secretary of State for Health what assessment he has made of the prescribing policy of Gloucestershire health authority of beta interferon; and if he will make a statement. [29309]
§ Ms Blears[holding answer 22 January 2002]: In Gloucestershire health authority beta interferon is prescribed to patients with relapsing/remitting multiple sclerosis who fulfil the clinical criteria of the guidelines of the Association of British Neurologists. The health authority has provided additional funding of £300,000 a year to meet the costs of this treatment. This policy will be reviewed following the publication of guidance by the National Institute for Clinical Excellence.